A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells

Cell Cycle

Volumn 9, Issue 6, 2010, Pages 1037-1042

  Kotani, Ai ^a   Ha, Daon ^b   Schotte, Diana ^c   Den Boer, Monique L ^c   Armstrong, Scott A ^d   Lodish, Harvey F ^b,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

miR 128; mirna; Mutation; Processing; Steroid resistance

Indexed keywords

GLUCOCORTICOID; HYBRID PROTEIN; MICRORNA; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CHROMOSOME TRANSLOCATION; DOWN REGULATION; FUSION GENE; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE; NONHUMAN; ONCOGENE; POINT MUTATION; PROGNOSIS; RNA PROCESSING;

EID: 77953528169     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.6.11011     Document Type: Article

References (27)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116:281-97.
2. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 304:594-6.
3. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs Results in Target mRNA Degradation. Cell 2005; 122:553-63.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20.
5. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5.
6. Xiao C, Calado D, Galler G, Thai T, Patterson H, Wang J, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131:146-59.
7. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303:83-6.
8. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 2007; 104:7080-5.
9. Li Q, Chau J, Ebert P, Sylvester G, Min H, Liu G, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129:147-61.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8.
11. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61.
12. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635-47.
13. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753-6.
14. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004; 39:167-9.
15. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435:828-33.
16. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103:7024-9.
17. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17:700-6.
18. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370:240-50.
19. kip1) expression 10.1073/pnas.0506464102. PNAS 2005; 102:14028-33.
20. Caslini C, Serna A, Rossi V, Introna M, Biondi A. Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. Leukemia 2004; 18:1064-71.
21. Gaussmann A, Wenger T, Eberle I, Bursen A, Bracharz S, Herr I, et al. Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation. Oncogene 2006.
22. Bursen A, Moritz S, Gaussmann A, Dingermann T, Marschalek R. Interaction of AF4 wild-type and AF4.MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology? Oncogene 2004; 23:6237-49.
23. Kotani A, Ha D, Hsieh J, Rao P, Schotte D, den Boer M, et al. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009; 114:4169-78.
24. Furuichi Y, Goi K, Inukai T, Sato H, Nemoto A, Takahashi K, et al. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. Cancer Res 2007; 67:9852-61.
25. Iwai N, Naraba H. Polymorphisms in human premiRNAs. Biochem Biophys Res Commun 2005; 331:1439-44.
26. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793-801.
27. Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 2006; 66:6097-104.